维普中文期刊产品整合服务
1篇 您的检索式:作者名="Ashujit Tagde"
    题名 作者 年代 出处 被引量
1Targeting MUC1-C suppresses BCL2A1 in triple-negativebreast cancer显示文摘B-cell lymphoma 2-related protein A1(BCL2A1)is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs;however,there are presently no agents that target BCL2A1.The MUC1-C oncoprotein is aberrantly expressed in triple-negative breast cancer(TNBC)cells,induces the epithelial–mesenchymal transition(EMT)and promotes anti-cancer drug resistance.The present study demonstrates that targeting MUC1-C genetically and pharmacologically in TNBC cells results in the downregulation of BCL2A1 expression.The results show that MUC1-C activates the BCL2A1 gene by an NF-κB p65-mediated mechanism,linking this pathway with the induction of EMT.The MCL-1 anti-apoptotic protein is also of importance for the survival of TNBC cells and is an attractive target for drug development.We found that inhibiting MCL-1 with the highly specific MS1 peptide results in the activation of the MUC1-C→NF-κB→BCL2A1 pathway.In addition,selection of TNBC cells for resistance to ABT-737,which inhibits BCL-2,BCL-xL and BCL-W but not MCL-1 or BCL2A1,is associated with the upregulation of MUC1-C and BCL2A1 expression.Targeting MUC1-C in ABT-737-resistant TNBC cells suppresses BCL2A1 and induces death,which is of potential therapeutic importance.These findings indicate that MUC1-C is a target for the treatment of TNBCs unresponsive to agents that inhibit anti-apoptotic members of the BCL-2 family.Masayuki Hiraki Takahiro Maeda Neha Mehrotra Caining Jin Maroof Alam Audrey Bouillez Tsuyoshi Hata Ashujit Tagde Amy Keating Surender Kharbanda Harpal Singh Donald Kufe 2018Signal Transduction and Targeted Therapy2018,3,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费